Reasons for withdrawal/discontinuation of treatment
| . | Atezolizumab . | Azacitidine . | ||||
|---|---|---|---|---|---|---|
| R/R MDS . | 1L MDS . | R/R MDS . | 1L MDS . | |||
| Cohort A (n = 11) . | Cohort B (n = 14) . | Cohort C (n = 21) . | Cohort A (n = 11) . | Cohort B (n = 14) . | Cohort C (n = 21) . | |
| Received at least 1 dose of study treatment | 11 (100) | 14 (100) | 21 (100) | NA | 14 (100) | 21 (100) |
| Withdrawn from treatment | 11 (100) | 14 (100) | 21 (100) | NA | 8 (57.1) | 21 (100) |
| Reason for discontinuation | ||||||
| Death | 1 (9.1) | 2 (14.3) | 3 (14.3) | NA | 1 (7.1) | 3 (14.3) |
| AE | 0 | 3 (21.4) | 2 (9.5) | NA | 2 (14.3) | 2 (9.5) |
| PD | 6 (54.5) | 4 (28.6) | 5 (23.8) | NA | 1 (7.1) | 6 (28.6) |
| Physician decision | 3 (27.3) | 1 (7.1) | 4 (19.0) | NA | 1 (7.1) | 4 (19.0) |
| Withdrawal by patient | 0 | 3 (21.4) | 3 (14.3) | NA | 3 (21.4) | 3 (14.3) |
| Lack of efficacy | 0 | 1 (7.1) | 0 | NA | 0 | 0 |
| Lost to follow-up | 0 | 0 | 1 (4.8) | NA | 0 | 0 |
| Other | 1 (9.1) | 0 | 3 (14.3) | NA | 0 | 3 (14.3) |
| . | Atezolizumab . | Azacitidine . | ||||
|---|---|---|---|---|---|---|
| R/R MDS . | 1L MDS . | R/R MDS . | 1L MDS . | |||
| Cohort A (n = 11) . | Cohort B (n = 14) . | Cohort C (n = 21) . | Cohort A (n = 11) . | Cohort B (n = 14) . | Cohort C (n = 21) . | |
| Received at least 1 dose of study treatment | 11 (100) | 14 (100) | 21 (100) | NA | 14 (100) | 21 (100) |
| Withdrawn from treatment | 11 (100) | 14 (100) | 21 (100) | NA | 8 (57.1) | 21 (100) |
| Reason for discontinuation | ||||||
| Death | 1 (9.1) | 2 (14.3) | 3 (14.3) | NA | 1 (7.1) | 3 (14.3) |
| AE | 0 | 3 (21.4) | 2 (9.5) | NA | 2 (14.3) | 2 (9.5) |
| PD | 6 (54.5) | 4 (28.6) | 5 (23.8) | NA | 1 (7.1) | 6 (28.6) |
| Physician decision | 3 (27.3) | 1 (7.1) | 4 (19.0) | NA | 1 (7.1) | 4 (19.0) |
| Withdrawal by patient | 0 | 3 (21.4) | 3 (14.3) | NA | 3 (21.4) | 3 (14.3) |
| Lack of efficacy | 0 | 1 (7.1) | 0 | NA | 0 | 0 |
| Lost to follow-up | 0 | 0 | 1 (4.8) | NA | 0 | 0 |
| Other | 1 (9.1) | 0 | 3 (14.3) | NA | 0 | 3 (14.3) |
1L, frontline; NA, not applicable.